Home › Pivotal Phase 3 Studies of Bezlotoxumab, Mercks Investigational Antitoxin to Prevent Clostridium Difficile Infection Recurrence, Met Primary Endpoint
 

Keywords :   


Pivotal Phase 3 Studies of Bezlotoxumab, Mercks Investigational Antitoxin to Prevent Clostridium Difficile Infection Recurrence, Met Primary Endpoint

2015-09-20 18:30:00| Merck.com - Research & Development News

Dateline City: KENILWORTH, N.J. Company Plans to Submit New Drug Applications in U.S., EU and Canada in 2015 Results Presented for the First Time at ICAAC/ICC 2015 Annual Meeting KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the two pivotal Phase 3 clinical studies for bezlotoxumab, its investigational antitoxin for prevention of Clostridium difficile (C. difficile) infection recurrence, met their primary efficacy endpoint: the reduction in C. difficile recurrence through week 12 compared to placebo, when used in conjunction with standard of care antibiotics for the treatment of C. difficile. Language: English Contact: MerckMedia Contacts:Doris Li, 908-246-5701Ian McConnell, 973-901-5722orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more

Tags: met primary studies prevent

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
29.09Eastern North Pacific Tropical Weather Outlook
28.09Hurricane Isaac Graphics
28.09Hurricane Isaac Forecast Discussion Number 12
28.09Tropical Storm Joyce Graphics
28.09Hurricane Isaac Wind Speed Probabilities Number 12
28.09Hurricane Isaac Forecast Advisory Number 12
28.09Hurricane Isaac Public Advisory Number 12
28.09Summary for Hurricane Isaac (AT5/AL102024)
More »